ArticleFrontiers in immunology2026
Aberrant long-chain fatty acids metabolism and its interplay with immuno-inflammatory responses in relapsing-remitting multiple sclerosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral metabolomic profiling reveals lipid and amino acid alterations associated with immuno-inflammatory responses in treatment-naïve late-onset Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growing evidence indicates significant alterations in fatty acid metabolism in patients with relapsing-remitting multiple sclerosis (RRMS). However, the metabolic status of long-chain fatty acids (LCFAs), including mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty acids (PUFAs), and their potential link to immune-inflammatory responses during RRMS relapses, remain unclear. This study aims to uncover the aberrant metabolic signatures of LCFAs, potential LCFA biomarkers during RRMS relapses, and their interactive network with peripheral inflammatory responses. Methods: In this study, plasma samples from 20 RRMS patients and 22 age- and sex-matched healthy controls (HCs) were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based untargeted metabolomics method. Results: Metabolomics analysis revealed marked changes in the LCFA metabolic profile of RRMS patients. Compared to HCs, 26 differentially abundant metabolites (DAMs) belonging to amino acids, fatty acids, and their derivatives were identified in RRMS samples, including significantly upregulated LCFA palmitic acid (FA 16:0) ( Conclusion: Our results uncover the aberrant metabolic features of LCFAs and potential biomarkers in RRMS patients, and the interactive network and key molecular nodes between LCFAs and peripheral immune-inflammatory responses. The interplay between LCFAs and immuno-inflammation may drive the migration of inflammatory events from the periphery to the CNS, reigniting CNS neuroinflammation and causing RRMS relapses. These findings offer valuable insights for RRMS diagnosis and novel therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.